KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Finished Goods data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Finished Goods fell 69.37% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, down 69.37%, while the annual FY2024 figure was $5.0 million, 232.49% up from the prior year.
  • Finished Goods reached $1.8 million in Q3 2025 per RIGL's latest filing, down from $2.7 million in the prior quarter.
  • Across five years, Finished Goods topped out at $5.8 million in Q3 2024 and bottomed at $962000.0 in Q1 2021.
  • Average Finished Goods over 5 years is $2.3 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Finished Goods: skyrocketed 232.49% in 2024, then tumbled 69.37% in 2025.
  • A 5-year view of Finished Goods shows it stood at $1.3 million in 2021, then skyrocketed by 45.12% to $1.9 million in 2022, then dropped by 20.8% to $1.5 million in 2023, then surged by 232.49% to $5.0 million in 2024, then plummeted by 64.38% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $1.8 million in Q3 2025, $2.7 million in Q2 2025, and $3.8 million in Q1 2025.